Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma

Shinkichi Takamori, 1 Takashi Seto, 1 Mikako Jinnouchi, 2 Taro Oba, 1 Masafumi Yamaguchi, 1 Mitsuhiro Takenoyama 1 1Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan; 2Department of Radiology, National Hospital Organization Kyushu Cancer...

Full description

Bibliographic Details
Main Authors:	Takamori S, Seto T, Jinnouchi M, Oba T, Yamaguchi M, Takenoyama M
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-01-01
Series:	Therapeutics and Clinical Risk Management
Subjects:	non-small cell lung cancer ros1 crizotinib rapidly destructive coxarthrosis
Online Access:	https://www.dovepress.com/rapidly-destructive-coxarthrosis-as-a-potential-side-effect-of-crizoti-peer-reviewed-article-TCRM

Similar Items

Rapidly destructive coxarthrosis accompanied by fluctuating C‐reactive protein level
by: Hayato Shimizu, et al.
Published: (2021-11-01)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
by: Mehta A, et al.
Published: (2020-02-01)

COMPLEX CHARACTERISTICS OF PATIENTS WITH COXARTHROSIS IN IRKUTSK REGION
by: V. A. Koryak, et al.
Published: (2012-04-01)

Crizotinib resistance conferred by BRAF V600E mutation in non–small cell lung cancer harboring an oncogenic ROS1 fusion
by: Shuang Ren, et al.
Published: (2021-01-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
by: Moushumi Suryavanshi, et al.
Published: (2017-01-01)

Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report
by: Shikang Zhao, et al.
Published: (2021-10-01)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
by: Jun Cao, et al.
Published: (2022-10-01)

IMMUNOPATHOLOGIC MANIFESTATIONS IN PATIENTS WITH SEVERE FORMS OF COXARTHROSIS
by: L. A. Dmitrieva, et al.
Published: (2014-07-01)

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
by: Yi-Long Wu, MD, et al.
Published: (2022-10-01)

Effects of local and whole-body cryotherapy on hip pain and general activity in the course of coxarthrosis
by: Widłak Patrycja, et al.
Published: (2023-01-01)

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
by: Jaime L. Schneider, MD, PhD, et al.
Published: (2022-07-01)

FEATURES OF IMMUNE STATUS IN ADOLESCENTS WITH COXARTHROSIS
by: M. V. Chepeleva, et al.
Published: (2016-10-01)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
by: Woo Kyung Ryu, et al.
Published: (2022-10-01)

STATE OF VEGETATIVE INTENSITY OF FUNCTIONAL SYSTEMS OF ORGANISM OF PATIENTS WITH DYSONTOGENETIC COXARTHROSIS AT THE TREATMENT BY ILIZAROV APPARATUS
by: E. V. Oleinikov, et al.
Published: (2012-07-01)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
by: Terry L. Ng, et al.
Published: (2022-12-01)

TO THE PROBLEM OF PATHOMORPHOLOGY OF FEMORAL HEAD AT THE III-IV STAGES OF COXARTHROSIS
by: O. A. Goldberg, et al.
Published: (2012-07-01)

Clinico-diagnostic peculiarities of dysplastic coxarthrosis of III-IV degree
by: V. F. Lebedev, et al.
Published: (2013-02-01)

Assessment of the impact of the rehabilitation procedure on functional and clinical condition of patients with coxarthrosis
by: Dariusz Jankowski, et al.
Published: (2014-03-01)

Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
by: Hyeon Hwa Kim, et al.
Published: (2024-01-01)

Efficiency of use of autologous activated serum in coxarthrosis
by: S M Noskov, et al.
Published: (2012-08-01)

Renal Abscess Caused by Crizotinib: A Rare Case Report
by: Zhaojun Wan, et al.
Published: (2022-07-01)

Changes in the immunological reactivity in patients with coxarthrosis and the factors that determine them
by: L. A. Dmitrieva, et al.
Published: (2022-12-01)

COMPLEX HEALTH-RESORT THERAPY OF COXARTHROSIS AND OSTEOPENIA IN POSTMENOPAUSAL WOMEN
by: A.S. KAYSINOVA, et al.
Published: (2017-09-01)

Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report
by: Danila Comandini, et al.
Published: (2021-06-01)

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
by: Jaclyn M. Beca, et al.
Published: (2021-10-01)

Markers of systemic inflammatory response in coxarthrosis
by: Korshunov G.V., et al.
Published: (2013-12-01)

Clinical Research of Crizotinib in Advanced Non-small Cell Lung Cancer
by: Haibo ZHU, et al.
Published: (2013-06-01)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
by: An-guo Chen, et al.
Published: (2022-03-01)

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
by: Mizuha Haraguchi Hashiguchi, et al.
Published: (2021-09-01)

Possibilities of treatment by radiofrequency denervation in coxarthrosis of various stages
by: Mikhail A. Gorokhov, et al.
Published: (2023-07-01)

Analysis of factors affecting the quality of life of patients with coxarthrosis
by: Redlicka Justyna, et al.
Published: (2017-06-01)

Morphometric justification of algorithm of the choice of method of surgical treatment of dysplastic coxarthrosis
by: Norkin I.A., et al.
Published: (2015-06-01)

Relationship of Immune Status Indicators and Hormonal Profile in Patients with Coxarthrosis
by: L. A. Dmitrieva, et al.
Published: (2019-12-01)

Arthroplasty of protrusion coxarthrosis in the patient with end-stage renal disease
by: A. N. Tsed, et al.
Published: (2018-12-01)

Biomechanical aspects of spine sagittal balance in patients with coxarthrosis in total hip replacement (preliminary study)
by: Oksana G. Prudnikova, et al.
Published: (2019-09-01)

Epidemiological assessment of the prevalence of coxarthrosis according to reports from medical organizations
by: V. A. Koryak, et al.
Published: (2022-05-01)

Morphology of bone structures of hip joint in normal state and in dysplastic coxarthrosis
by: Anisimova Е.А., et al.
Published: (2014-09-01)

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report
by: Hiromune Sawada, et al.
Published: (2023-12-01)

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
by: Yongchang Zhang, et al.
Published: (2021-09-01)

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report
by: Shibo Wu, et al.
Published: (2018-07-01)